首页> 外文OA文献 >CD137+CD154− Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from In Vitro Expansion Cultures
【2h】

CD137+CD154− Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from In Vitro Expansion Cultures

机译:CD137 + CD154-表达作为调节性T细胞(Treg) - 特异性活化签名,用于识别和分类来自体外膨胀培养物的稳定人体Tregs

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Regulatory T cells (Tregs) are an attractive therapeutic tool for several different immune pathologies. Therapeutic Treg application often requires prolonged in vitro culture to generate sufficient Treg numbers or to optimize their functionality, e.g., via genetic engineering of their antigen receptors. However, purity of clinical Treg expansion cultures is highly variable, and currently, it is impossible to identify and separate stable Tregs from contaminating effector T cells, either ex vivo or after prior expansion. This represents a major obstacle for quality assurance of expanded Tregs and raises significant safety concerns. Here, we describe a Treg activation signature that allows identification and sorting of epigenetically imprinted Tregs even after prolonged in vitro culture. We show that short-term reactivation resulted in expression of CD137 but not CD154 on stable FoxP3+ Tregs that displayed a demethylated Treg-specific demethylated region, high suppressive potential, and lack of inflammatory cytokine expression. We also applied this Treg activation signature for rapid testing of chimeric antigen receptor functionality in human Tregs and identified major differences in the signaling requirements regarding CD137 versus CD28 costimulation. Taken together, CD137+CD154− expression emerges as a universal Treg activation signature ex vivo and upon in vitro expansion allowing the identification and isolation of epigenetically stable antigen-activated Tregs and providing a means for their rapid functional testing in vitro.
机译:调节性T细胞(Tregs)是几种不同免疫病理的有吸引力的治疗工具。治疗性Treg应用通常需要长时间的体外培养物产生足够的Treg数或优化其功能,例如,通过其抗原受体的基因工程。然而,临床Treg膨胀培养物的纯度具有高度变化,目前,不可能将稳定的Tregs识别和将稳定的Tregs与污染效应T细胞,以外的渗透剂,或在先前的膨胀后分离。这代表了扩展特雷格斯质量保证的主要障碍,并提高了严重的安全问题。这里,我们描述了一种Treg激活签名,即使在长期的体外培养后,即使在长期的体外培养后,也允许识别和分类表述印迹的Tregs。我们表明短期重新激活导致CD137的表达,但在稳定的Foxp3 + Treg上表达CD154,其显示出脱甲基化的Treg特异性去甲基化区域,高抑制潜力和缺乏炎症细胞因子表达。我们还应用了这种Treg激活签名,以便快速测试人类Tregs中的嵌合抗原受体功能,并确定了关于CD137与CD28成果刺激的信号传导要求的主要差异。一起服用CD137 + CD154--表达作为通用Treg激活特征,并且在体外扩张后,允许鉴定和分离外膜稳定的抗原活化的Tregs并提供其在体外快速功能测试的方法。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号